Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.59 |
| ▸ | USP7 | Q93009 | 2/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24511982 | 1.00 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24511965 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12686514 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24511969 | 0.92 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12968255 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22964819 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12968254 | 0.91 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22964815 | 0.91 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12968074 | 0.91 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22964816 | 0.91 | MBOAT4 (0.63) | NOS2KEAP1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | REATA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190350941-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-2683731-B1 | C4-MONOMETHYL TRITERPENOID DERIVATIVES AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190091194-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20120252776-A1 | C4 Monomethyl Triterpenoid Derivatives and Methods of Use Thereof | REATA PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012125488-A1 | C4-MONOMETHYL TRITERPENOID DERIVATIVES AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350941-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | NOS2 3518/4885KEAP1 694/4885CYP3A4 2497/4885 |
| US-20190091194-A1 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | EDNRA, EDNRB, CYP11B1 | NOS2 40/4885KEAP1 53/4885CYP3A4 3779/4885 |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | NOS2 3518/4885KEAP1 694/4885CYP3A4 2497/4885 |
| US-20230255982-A1 | METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF | CYP17A1, HSD11B2, HSD11B1 | NOS2 471/4885KEAP1 207/4885CYP3A4 1144/4885 |
| US-20120252776-A1 | C4 Monomethyl Triterpenoid Derivatives and Methods of Use Thereof | CYP4A11, LTC4S, NOX4 | NOS2 245/4885KEAP1 44/4885CYP3A4 33/4885 |
| US-10953020-B2 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | HSD11B2, CYP21A2, HSD11B1 | NOS2 3518/4885KEAP1 694/4885CYP3A4 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.